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ABSTRACT
External wounds such as cuts, abrasions, lacerations and in cases deep wounds like
gunshot wound or even burns are included in common causes of death as they lead to heavy
blood loss from human body. Prevention for these issues are use of hemostatic agent in the
preliminary stage thereby impeding blood loss for 30 minutes to 1 hour at least and alleviate
hypovolemic shock induced deaths in humans. Numerous wound dressing materials have
been developed in last few decades which use simple , readily available biomaterials to
prepare hemostatic agents either in the form of powder, or gauge or sponge material or
beads etc. Almost all commercially available agents are found to have excellent desired
characteristics as a wound dressing even though almost each of them lack some major
characteristics. For a dressing to be ideal it should be highly hemocompatible, it should have
antimicrobial properties, it should be hydrophilic, should have moisture content, should be
able to remove easily, should be flexible to use in all types of wounds, not just superficial,
flat wounds and lastly it should absorb all the exudates.
Some of the commercially available wound dressing agents are QuickClot, Hemcon
Chitogauge, Cel-X etc. QuickClot (Z-Medica)is composed of mineral zeolite powder with
a 3D honeycomb structure that allows it to sift molecules by size. When comes in contact
with blood, it absorbs water molecules increasing the clotting factors and cell concentrations
at the wound. This readily forms clot at the wounded site. However QuickClot was found
to have a severe side effect. It appeared to be exothermic and caused local tissue burn at the
wounded site. Also use of granular form QuickClot was difficult. Once clot is formed, the
powder could only be extracted by surgery. Hemcon , made up of chitosan is a stiff dressing
and thus is limited only to superficial wounds. For deep wounds more advanced ChitoFlex
and ChitoGauge are used.
Keywords: Polyelectrolyte complex; Bentonite;Wound dressing; Hemorrhage
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Chapter 1
Introduction
1.1 Wound healing process in human
1.1.1 Wound
An injury or damage to the integrity of skin, muscle, bone or any tissue of the body by
physical means which causes disruption to the normal continuity of structure can be termed
as a wound. They can be categorized into abrasion, avulsions, contusions, crush wounds,
cuts, lacerations, deep wounds/ velocity wounds and punctures. Depending on the severity
they may cause infection, inflammation or even scar formation.
1.1.2 Wound healing
Wound healing is a spontaneous action by the body to counteract the effects of an injury
and maintain the integrity of a conventional structure. In this complex and dynamic process,
devitalized cellular structures get replaced, and tissue layers regrowth occurs. The process
can be one of the two ways. Healing by primary intention or healing by secondary intention,
which depending upon the intensity of wound. A small puncture or cut can heal completely
within two or three days. However, in the case of severe injuries, it takes time for the
body to heal properly. The complex series of events include chemotaxis, phagocytosis,
neocollagenesis, collagen degradation, collagen remodelling, angiogenesis, epithelization,
and the production of new glycosaminoglycans (GAGs) and proteoglycans.
The overall wound healing process can be described under 4 distinct phases.
• Hemostatic phase
• Inflammatory phase
• Proliferation phase
• Maturation phase
The first phase can be regarded as human body’s natural response to the wound.
A wound usually disrupts the blood vessels and further response from the body starts
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with vasoconstriction followed by a series of complex biochemical reactions called
as haemostasis. Here platelets adhere to the wounded site and release cytokines,
chemokines, and hormones [1]. Epinephrine, norepinephrine, prostaglandins, serotonin,
and thromboxane are called vasoactive mediators and cause blanching of the wound
temporarily. Platelet activation leads to the release of chemokines whose function is to attract
inflammatory cells to the area. This process leads to the next phase in the healing process.
Studies show that a defective formation of clot such as the absence of fibrin stabilising factor
in clot affects wound healing [2].
After the completion of haemostasis, blood vessels dilate, through a process known
as vasodilation which is guarded by some hormonal changes in the body. This allows
cells, antibodies, growth factors, nutrients, etc. to reach the wounded area and accelerate
the healing. This vasodilation is mediated by histamine, prostaglandins, kinins, and
leukotrienes. However, this leads to the excessive deposition of exudates at the site of
injury. Following signs of maceration needs to be monitored. The characteristic signs
of inflammation like erythema, heat, edema, pain can be seen and felt during this period.
The phagocytic cells; neutrophils, polymorphonucleocytes and local mast cells are the
predominantly work in this phase. Any devitalised necrotic tissues are autolysed as a host
response effect. They provide the first line of defence against any infection. Broken fibrin
is cleaned up as and along with the degradation product.
During proliferation phase, the wounded site is restructured at a cellular level with new
tissue consisting of collagen and extracellular matrix. Organisation of a new network of
blood vessels develop. The process is called angiogenesis. Healthy granulation starts on the
epithelial layers. However, the rate of granulation highly depends upon the fibroblasts and
availability of sufficient oxygen and nutrients. Healthy granulation tissue is an amorphous
structure, granular and uneven in texture providing the restriction to bleeding. A granulation
pink or red in appearance indicates a healthy granulation tissue whereas dark granulation
tissue can be indicative of ischaemia or poor perfusion. Epithelial cells finally resurface the
wound.
Maturation is the final phase. It begins after the wound closer. Type III collagen is
remodelled into type I collagen. Cellular activities decrease at the wound site and the number
of blood vessels in the wounded area regress and decrease.
A complete but abnormal wound healing can be characterized by the production of
an exuberance of fibroblastic proliferation which can result in hypertrophic scar or keloid
formation. Insufficient wound healing may result in hypotrophic or atrophic scar formation.
From the above discussion, it is evident that skin is regarded as the first line of defence
followed by blood. The blood with its unique chemistry and constituent cells provides a
strong line of defence against microorganisms and maintain regular activities.
2
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Figure 1.1: Stages of wound healing (source:https://www.pinterest.com/pin/)
1.1.3 Blood cells and other wound healing mediators
Blood is a specialized body fluid which transports micro andmacro nutrients, gases and other
metabolites needed for life sustaining, either dissolved in plasma or through conjugation
with protein entities present in human body. Blood vessel endothelium has some important
regulation mechanism to impart along with functional defence of blood and its cells. The
vascular endothelium secretes locally acting messengers such as prostaglandins, nitric
oxide (NO) and peptides CNP and endothelin-1. They maintain vascular homeostasis and
influence processes like blood pressure, cell proliferation etc. Prostaglandins are involved
with clotting. Prostacyclin (PGI2) has anticoagulant properties. PGI2 along with nitric
oxide, NO (one of the EDRFs) acts as vasodilator and are used in second stage of wound
healing. Thromboxane (TXA2) is a procoagulant and is derived from platelets. NO-induced
production of cyclic GMP is responsible for:
• Vasorelaxation (the EDRF effect) in vascular smooth muscle cells (VSMC)
• Inhibition of proliferation of VSMC and endothelial cells
• Inhibition of platelet adhesion and aggregation on endothelium
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• Inhibition of endothelial apoptosis (at low NO concentration)
In general, blood is composed of plasma, blood cells, and different micro and
macromolecules including proteins. Blood plasma is almost 92% water by volume and
constitutes almost 55% of blood volume. It carries different proteins which help clotting
as secondary defence mechanism. The cells present in blood are:
• Erythrocytes
• Thrombocytes
• Leukocytes
– Granulocytes
* Eosinophil
* Basophil
* Neutrophil
– Agranulocytes
* Monocytes
* Lymphocytes
Erythrocytes
During dermal wound healing erythrocytes are believed to affect the extracellular matrix
protein expression of dermal fibroblasts. Some studies also include the hypothesis of dermal
fibroblast matrix metalloproteinase (MMP)-1 level being affected by RBCs. MMPs have
role in ECM remodelling.
Through the studies of Greiling et al. a relation has been established between fibronectin
production and re-epithelialization of wounded site. Fibronectin in conjunction with PDGFs
promote the expression of appropriate receptors. The migration of the former from the
periwound stroma into the fibrin clot for the initiation of the re-epithelialization process is
followed by signalling to fibroblasts and keratinocytes [3]. Hence, RBC has a passive effect
on re-epithelialization as post wound healing procedure by the upregulation of fibronectin.
Thrombocytes
In normal flowing condition platelets are biconvex, although when treated with EDTA
they appear somewhat spherical. Under certain conditions like rupture to wall vessel or
damaged tissue condition, stored blood platelets migrate from the spleen to the peripheral
blood. They change their surface structure and characteristics, become irregular and sticky,
extending pseudopods. They adhere to nearby surfaces or form clump adhering to each
other. The platelet glycocalyx is thicker than cell membranes of leukocytes and erythrocytes
4
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being 20-30 nm in thickness. This thick layer possess high adherence property thereby
responds readily to hemostatic demands. The platelet surface charge is negative. It carries its
functional environment with it, meanwhile repels other platelets, other blood cells, and the
cells of blood endothelium all with similar negative charge surface. The plasma membrane
protrude inward towards the platelet interior and produce its unique surface-connected
canalicular system (SCCS), which are twisted throughout the platelets and store proteins
used in abnormal hemorrhagic condition. Dense tubular system (DTS), a remnant of the
rough endoplasmic reticulum, lay parallel to the glycocalyx membrane. The DTS sequesters
Ca2+ and bears carries enzymes like phospholipase A2, cyclooxygenase, and thromboxane
synthetase which are involved in platelet activation process. The discoid shape of platelet is
maintained by a circumferential bundle of microtubules. The later get reassembled in long
parallel bundles forming pseudopods during platelet shape change to provide rigidity.
There are mainly two types of secretion vesicles in platelets. The dense granules and
the -granules. The -granules are filled with proteins, VWF, thrombin and certain growth
factors. Upon platelet activation - granule membranes fuse with the SCCS. Proteins from
α- granules flow to the nearby microenvironment. There they participate in platelet adhesion
and aggregation and support plasma coagulation. Along with 50-80 numbers of -granules
there dense bodies otherwise called dense granules present 2 – 7 in number, per platelet.
Basophil
Basophils contain heparin, an anticoagulant which acts on Factor X and prevents blood from
clotting too quickly by inhibiting prothrombin to thrombin conversion. They also contain
the vasodilator histamine, promotes blood flow to tissues.
Eosinophils
These are regarded as source of cytokines transforming growth factor, TGF-and TGF-along
with macrophages, neutrophils, keratinocytes, fibroblasts, and endothelial cells [4].
Neutrophils
Neutrophils being the first immune cell types to reach the wound bed through migration
are activated by microbial or inflammatory stimuli. The activation of neutrophils causes
the release cell-free DNA, histones, and antimicrobial proteins. Cell-free DNA (CFDNA)
activates the intrinsic pathway of coagulation. Histones released in the process take part in
platelet-dependent mechanisms to promote thrombin generation [5].
Monocyte
These are the second immune cell type to migrate towards wound bed. The process is
facilitated bymonocyte chemoattractant protein-1 (MCP-1) which help the migration as well
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as a transformation of the monocytes cells into macrophages. The later disposes of the debris
and neutrophils through phagocytosis.
1.1.4 Mechanism of Coagulation
Severe blood loss from ruptured blood vessels is called hemorrhage. The body has its
complex and coordinated mechanism of controlling hemorrhage, known as hemostasis.
Hemostasis involves vasoconstriction and forms the clot at the injured site. The process starts
from the activation of platelets at the site of injury to complete healing of the tissue. Damaged
endothelium at injured site release EndotheliumDerived Contraction Factors (EDCFs), some
unique peptide endothelin, leading to vasoconstriction. This limits the flow of blood to the
wound bed.
Platelet activation
A break in endothelium, exposes the collagen underneath. Platelets get adhered to collagen
exposed from damaged endothelium by an von Willebrand factor (vWF) mediated reaction.
The vWF connects platelet surface to collagen fibrils by forming a bridge between a specific
glycoprotein complex on the surface of platelets (GPIb-GPIX-GPV) and collagen fibrils.
Also vWF stabilizes coagulation factor VIII in normal circulation by binding to the active
site.
Platelets adhere to one another through fibrinogen present already in blood and to
collagen under the endothelium through vWF, forming a platelet plug. On the surface of the
activated platelet are glycoprotein IIb/IIIa and VWF receptors. Which provides the site of
adherence to fibrinogen. The binding of fibrinogen by glycoprotein IIb/IIa on two platelets
causes platelets to adhere to each other. Activated platelets form pseudopods which help
them adhere to one another and to wound surface. A little of the fibrinogen is released from
the alpha granules also.
The release of intracellular Ca2+, activates myosin light chain kinase (MLCK) enzyme.
Formation of pseudopods is facilitated by activation of MLCK, which then phosphorylates
the light chain of myosin. The later then interacts with actin protein in platelet cytoskeleton,
resulting in altered platelet morphology and motility. Thus as the platelet is activated,
its shape changes to an amorphous form with pseudopods. Further process after platelet
activation can be explained in two pathways,
• The extrinsic pathway
• The Intrinsic pathway.
Both are initiated by distinct mechanisms and converge to lead the common pathway
finally producing a fibrin clot.
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Intrinsic pathway
Intrinsic pathway starts from contact phase which is initiated by interaction with the
phospholipids, primarily phosphatidylethanolamine (PE) of circulating lipoprotein particles
such as chylomicrons, VLDLs, and oxidized LDLs, when pre-kallikrein (PK), high
molecular weight kininogen (HMWK), Factor XI and factor XII are exposed to a negatively
charged surface. Contact activation can be initiated on bacterial surface as well. Urate
crystals, fatty acids, protoporphyrin, amyloid β, and homocysteine can interact with blood
to initiate contact activation.
After the contact phase components get adhered to potentially negative charged surface
(usually platelet plug), prekallikrein is converted to kallikrein. The later then activates
the factor XII (Hageman factor), an endopeptidase enzyme to factor XIIa. Factor XIIa
has two contributions in clotting cascade. It activates Factor XI (Plasma thromboplastin
antecedant) into factor Xia. It establishes a reciprocal activation cascade by hydrolyzing
more prekallikrein into kallikrein.
Factor XIa activates factor IX to factor IXa in presence of Ca2+ ion. Factor IX is
a proenzyme and contains vitamin K-dependent γ-carboxyglutamate (gla) residues. Its
glutamate residues binds to Ca2+ ions, serene protease activity is activated in result of that.
Factor II, VII, IX, and X are also gla-containing proenzymes. Activated factor IXa activates
factor Xa from factor X cleaving an internal arg-ile bond.
The formation of tenase complex is facilitated by presentation of phosphatidylserine (PS)
and phosphatidylinositol (PI) on their surfaces platelet membrane surface, which allows the
comprising Ca2+ ion and factors VIIIa, IXa and X. This activates factor Xa.
Factor VIII in this process acts as a receptor in activated form (VIIIa) providing binding
site for factors IXa and X. The presence of minute quantity of thrombin in circulation
activates factor VIII to factor VIIIa (the actual receptor). However the concentration of
thrombin establishes a feedback mechanism, which controls the extent of coagulation. As
the concentration of thrombin increases above a threshold, it cleaves factor VIIIa thus
inactivating it and controlling the extent of tenase complex formation as well.
Extrinsic Pathway
In case of external cut, bruise or any kind of external tissue injury, a localised transmembrane
receptor called Tissue factor is released by local tissue, which initiates extrinsic pathway as
an exogenous agent and thus the name. Tissue factor, also known as factor III is a cofactor
in the activation of factor X reaction mediated by factor VIIa. It is usually expressed by the
cells surrounding blood vessels. Trace amount of it are found in blood circulation, some
in liver and heart as well. It was found that TF present around blood vessels is found in
complex state bound with FVII, and gains individual form after injury [6].
Factor VIIa is a gla residue containing serine protease enzyme. It carries the
7
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activation reaction of factor X to factor Xa, with the help of TF. The extrinsic pathway
is controlled by a complex formed by TF and factor VIIa-Ca2+-Xa complex. The protein,
lipoprotein-associated coagulation inhibitor (LACI). . LACI is also known as anticonvertin
binds to this complex specifically inhibiting the extrinsic pathway. It is composed of 3
tandem protease inhibitor domains and forms a feedback loop controlling the extent of
extrinsic pathway. Domain 1 binds to factor Xa and domain 2 binds to factor VIIa in presence
of Xa.
The common pathway
Activation of Factor X to factor Xa is the common point of both intrinsic and
extrinsic pathway and marks the beginning of common pathway.. Factor Xa activates
factor II to factor IIa, thrombin. Thrombin facilitates the conversion of fibrinogen
to fibrin. The activated surface platelets play host to the prothrombinase complex
formation where the activation of thrombin occurs. This complex consists of the platelet
phospholipids (phosphatidylinositol and phosphatidylserine), Ca2+ ion, factors Va and Xa,
and prothrombin. Factor V has similar as that of factor VIII in tenase complex formation.
It works as a cofactor in the prothrombinase complex formation. Low concentration of
thrombin facilitates the activation of factor V (analogous to Factor VIII) and is inactivated
by increased levels of thrombin, working a feedback loop again.
Fibrinogen (factor I) in its inactivated normal form, forms a bridge between platelets by
binding to their GpIIb/IIIa surface membrane proteins during platelet activation process. It
is a hexamer and consists of 3 pairs of polypeptides ([Aα][Bβ][γ])2. The 3 pair polypeptide
chains are covalently linked at their N-terminals through disulfide bonds. The former
portions of the Aα and Bβ chains (the A and B component) comprise the fibrinopeptides,
A and B, respectively. Thrombin activates the release of the fibrinopeptides forms fibrin
monomeric units (αβγ)2. These monomers form a mesh like structure, spontaneously
aggregate to form a weak fibrin clot. In addition to fibrin activation, other functions of
thrombin involve convertion of factor XIII to factor XIIIa, This is a transglutaminase and
forms cross-linking bridges composed of covalent bonds between the amide nitrogen of
glutamines and ε-amino group of lysines in the fibrin monomers to make a strong clot.
1.1.5 Ideal dressing
An ideal dressing should be an efficient barrier to bacterial infection; it should be able
to maintain moisture environment around the wound bed, allow the gaseous exchange,
and be able to remove exudates to maintain a clean microenvironment. It should also be
non-allergenic, non-adherent, non-toxic, hemocompatible and when necessary should be
able to be removed easily without causing pain, the biomaterial should be readily available
and should require minimal processing, possess antimicrobial properties and promotes
8
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Figure 1.2: Clotting Cascade
wound healing.
1.1.6 Wound dressing material
History of wound dressing materials can be dated back to 1600 BC when plastic covered
Linen strips soaked in grease was used to occlude wounds. There has been evidence of use
of clay tablets by people from mesopotamian origin during 2500 BC. Hippocrates of Greece
used wool as bandage in boiling form, in water or alcohol [7]. Proper standardised wound
care began to establish during 20th century. In 1891 use of cotton gauge was established
whcich was in proper woven form with absorbant properties.
The following table is a summerized form of review of wound dressing materials [8].
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Table 1.1: Comercial wound dressing samples and their uses
Form of dressing Use Example
Semipermeable Superficial wound. Shallow wound
with low exudates
Opsite™, Tegaderm™
Semi-permeable foam Moderate to highly exudating
wounds, granulating wounds. Used
in lower leg ulcers.
Lyofoam™, Allevyn™
Hydrogels dressing Dry chronic wounds, necrotic
wounds. ulcers and burn wounds.
Intrasite™, Nu-gel™
Hydrocolloid dressing Moderately exudating wounds,
pressure sores, paediatric wound,
minor burn wounds, traumatic
wounds,
Granuflex™, Comfeel™
Alginate dressing Moderate to heavy drainagewounds Sorbsan™, Kaltostat™
Biological Suitable for diabetic foot ulcer and
venous leg ulcer.
Laserskin™, Biobrane ™
Medicated dressings Cleaning or debriding agents for
necrotic tissue, antimicrobials
Cutisorb™, DebridaceTM
Some of the commercially available wound dressing agents are QuickClot, Hemcon
Chitogauge, Cel-X etc. QuikClot from Z-Medica is a clay based bandage composed of
mineral zeolite powder with a 3D honeycomb structure that allows it to shift molecules
by size. When comes in contact with blood, when in aqueous medium it absorbs water
molecules thereby increasing the concentration of clotting factors blood cells at the wound
site. This readily forms clot. However Quickclot was found to have a severe side effect.
The reaction of it with blood is apprered to be exothermic and caused local tissue burn at the
wounded site [9]. Also use of granular form QuickClot was difficult. Once clot is formed,
the powder could only be extracted by surgery.
Hemcon , made up of chitosan is a stiff dressing and thus is limited only to superficial
wounds. For deep wounds more advanced ChitoFlex and ChitoGauge are used. Celox being
another dressing material in powder form is good for superficial wounds, but when used in
deep wounds , it may get carried away with the flow of blood and adhere somewhere inside
blood vessels forming clot [10].
Chapter 2
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Chitin was discovered in 1811 in France by prof Henri Braconnot and it was of fungal origin.
The name chitin comes in 1830s retrieved from the Greek etymology. It means “A Coat Of
Mail”. Later it was found in abundance from shells of shrimps, prawns and other crustaceans.
Chitosan was discovered in 1859 by prof C. Rouget. It is an alkaline deacetylation
product of chitin. The degree of deacetylation varies considerably and affects structural
and chemical properties of chitosan. The degree of deacetylation being close to 0% or 100%
yields a products promoting increased cell adhesion and decreased rate of degradation which
was not in the case of intermediate deacetylation [11]. Even being the second most abundant
natural polysaccharide, chitin has found very little usage due to its inertness. Chitosan is
a copolymer of two units names as (1 → 4)-2-acetamido-2-deoxy-β-D-glucan (N-acetyl
D-glucosamine) and (1→ 4)-2-amino-2-deoxy-β-D-glucan (D-glucosamine) [12]. The -OH
function of glucopyranose ring in chitosan are susceptible to nucleophilic attack. Typically,
the molecular weight of commercial chitosan has a varied range from 3.8-20 kDa.
Figure 2.1: Structure of chitin (i) and chitosan(ii)
The degree of acetylation determines the density of the amino groups in chitosan
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macromolecule. They behave as the cationic group as they can carry an extra positive charge
which is pH dependent, the later being the cause of degree of protonation. At high degree
of deacetylation chitosan exhibits an extended form and flexible polymeric chain whereas at
lower degree of deacetylation it adopts a more coiled rod like structure [13]
Chitosan containing a large number of amino groups in its structure which in fact imparts
to its cationic behavior also exhibits a pH-sensitive behavior as a weak polybases. Chitosan
dissolves frequently at low pH while at higher pH range it is almost impossible to dissolve.
Chitosan containing a large number of amino groups in its structure which in fact imparts to
its cationic behavior also exhibits a pH-sensitive character as a weak polybases . Chitosan
dissolves frequently at low pH while at higher pH range it is almost impossible to dissolve.
The protonation of amine groups in chitosan at only less pH conditions drives the pH
sensitive swelling properties. This protonation is followed by chain repulsion, diffusion
of H+ and opposite ions together with water inside the gel and dissociation of secondary
interactions. Preparation of chitosan hydrogels followed by scaffolds by the formation of
polyelectrolyte complexation substitutes effectively, the covalent cross-linking hydrogels.
PECs are usually biocompatible and exhibit good swelling behavior.
Chitosan provides a matrix for 3 dimensional tissue growth and activates macrophages
for tumoricidal activity [14]. Being a hemostat, it helps in conventional blood clotting and
blocks nerve endings and hence brings relief to at the injured site [15]. Cell proliferation and
tissue architectural onset is pivoted by chitosan [16]. It thereby depolymerizes to release
N-acetyl- β -D-glucosamine. This onsets proliferation of fibroblast and helps in collagen
deposition ot the site in order, also stimulates increased level of natural hyaluronic acid
synthesis at the wound site. It helps in increased rate of wound healing and scar prevention.
The inherent polycationic nature of chitosan makes it a potential analgesic material
[17]. The amino group (-NH2) along D-glucosamine residues are protonated at the site of
inflammation causing a relief of pain.
Chitosan being a natural polysaccharide bears covalent glycosidic bonds which are
breakable. Several proteases and mainly lysozyme degrade chitosan into variable length
oligosaccharides which are incorporated in normal metabolic activity of or can be excreted
[11].
In the early phase of wound healing, infiltrating polymorphonuclear leukocytes (PMN)
clean foreign agents in the wound area, while chitosan accelerates the infiltration of PMN,
consequently accelerating wound cleaning [18].
Positively charged chitosan surface can electrostatically attract the neuraminic acid
residues of RBC surface glycoprotein. Erythrocytes lose their typical biconcave shape
indicating their procoagulant activity. Further negatively charged blood proteins like
fibrinogen electrostatically attach to chitosan surface initiating platelet adhesion and
activation.
Chitosan has been found to have higher activated partial thromboplastin time (aptt time)
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Figure 2.2: Schematic representation of platelet activation on material surface [19]
showing a little delay in onset of intrinsic mechanism of blood clotting. This effect has been
attributed to a phenomenon called the “adsorption-dilution effect” which passively delays
the clotting time [19].
Figure 2.3: Schematic representation of benifits of chitosan on wound healing [20]
Alginate is a natural polysaccharide [21]. It is extracted from marine brown algae.
Alginate is copolymer with linear structure that consists of two polymeric links, i.e.
(1-4)-linked β -D-mannuronic acid (M) and a-L-guluronic acid (G) residues [22]. The two
monomeric units are of uronic acids and their relative concentration vary along the polymer
chain along with their arrangement, depending on the origin of the alginate. Alginate wound
dressings possess most of the desired properties of ideal wound care material. Hygroscopy,
bactericidal property at wounded site, and help in wound healing. Calcium alginate has been
found to have profound effect as a wound dressing material. Even there are commercialised
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alginate based products available in market for wound care and management. Calcium
alginate dressings have been found to provide a significant healing effect in STSGs (split
thickness skin graft) donor sites [23]. The pain severity significantly reduces in burn patients.
Its ease of care has been a great advantage for nursing personnel. The combined use
of calcium sodium alginate and a bio-occlusive membrane dressing with calcium alginate
eliminates the problem of seroma formation in the management of split skin graft donor
sites. Thomas et al. [24] have reported that alginates accelerate healing process by activating
macrophages to produce TNF-α which initiates inflammatory signals.
Polyelectrolytes are macromolecules which exhibit a net positive or negative charge
when dissolved in a polar solvent like water. When opposite charged polyelectrolytes come
into contact with each other , form polyelectrolyte complex or otherwise known as polysalts.
As the cationic and anionic polyelectrolyte get mixed, the reaction creates an exotherm as
entropy of the system shifts from ideal [25].
Chitosan and Alginate (both polyacids) being cationic and anionic in nature form such
polyelectrolyte complex. The resulting material is superior to both the individual ones in
strength and in some properties and provide optimal support to wound care. Studies on
chitosan, alginate polyelectrolyte complex have shown to have significant impact on wound
healing, promoting platelet adhesion and thereby coagulation in case of deep wounds and
burns as well.
Bentonite predominantly consists of montmorillonite: a clay mineral belonging to a class
of phyllosilicates called smectites. Bentonites may contain a variety of accessory minerals in
addition to montmorillonite.Its density when dry varies depending on the quality, and may
range from 2.2 to 2.8 g/cm3. The charge deficiencies of montmorillonite is described by
extensive isomorphous substitution for silicon and aluminium by other cations. Hydrated
water molecule and cations coexist between the unit layers and basal spacing varies from
few angstrom to infinity (after swelling). Several wound healing product like quikclot
have been developed using clay minerals like zeolite and are found to have better effect
on dressing material. QuickClot having zeolite releases Ca2+ ion into blood and thereby
causes improved clotting [26].
Chapter 3
PEC samples
3.1 Materials and Methods
Cell culture tasted Chitosan with degree of deacetylation greater than 90% and molecular
biology grade sodium alginate were obtained from HiMedia. Bentonite powder (Aluminium
Silicate hydrate) is obtained from Fisher scientific. The test results were compared with
HemCon ChitoGauze® PRO and Quikclot advanced clotting sponge. PT (Thromborel® S)
and APTT (Actin FSL) reagents were obtained from Siemens Healthcare.
3.1.1 Preparation of PEC Dressing
Chitosan solution (1% W/V) was prepared in water. Hydrochloric acid (HCl) was added
dropwise to maintain acidic pH. Sodium alginate was dissolved in water. pH of chitosan
solution was maintained around 5. Sodium alginate solution prepared has an acidic pH as
well (pH 6-6.5). Chitosan solution was taken in a syringe and dropwise added to alginate
solution. Beads are formed in alginate base. Ultrasonification of these samples were done to
prepare an uniformmixture which is the resultant PEC solution. The composition of the PEC
were varied starting from 70% chitosan-30% alginate with 10% decrement in chitosan and
10% increment in alginate concentration up to 30% chitosan-70% alginate. These solutions
were frozen at -200 C for 12 hours. Then the samples were lyophilised at -1200 C in a
lyophilizer. Resultant scaffold produced is the desired material to be tested. Scaffolds of
pure chitosan and alginate were also produced. For characterisation studies, Environmental
Scanning Electron Microscope (E-SEM), study was carried out.
3.1.2 Hemolysis Assay
Hemolysis assay was taken from Mallick et al. [27]. 0.9% NaCl solution was prepared by
diluting common salt in water. This is known as physiological saline. Blood is diluted with
physiological saline in the ratio of 4:5. The resulting solution forms the stock solution.
The dressings were cut into equal sizes (12 mg each). The dressings were placed into
polypropylene tubes and 0.5 mL of diluted blood was dispensed on them. Two different
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control (positive and negative) were also made. Same amount of blood was added to both
control, while .01MHClwas added to the positive control rupturing the RBC fraction. All the
tubes were diluted with physiological saline by similar amount. The tubes were centrifuged
at 2000g for 20 minutes. OD of the supernatants was taken at 540 nm.
Hemolysis% = ODtest  OD ve
OD+ve  OD ve×100 (3.1)
Samples having hemolysis percentage <5% are highly hemocompatible, 5-20% are semi
hemocompatible and samples having hemolysis percentage above 20
3.1.3 Blood Clotting Assay
The whole blood clotting assay was taken from Shih et al. [28] and was modified. The
dressings were placed into 50 mL polypropylene tubes and pre-warmed to 37⁰C. 200 μL of
anticoagulated whole blood was then dispensed onto the dressings. 20 μL of 0.2 M calcium
chloride was added to initiate coagulation. After 10 min incubation at 37ºC and 30 rpm, the
RBCs that were not trapped in the clot were hemolysed by pouring 25 mL distilled water
slowly along the walls of the tube. This was done in an interval of 5, 10, 15, 20 minutes.
The absorbance (OD) of the resulting hemoglobin solution was taken at 540 nm.
3.1.4 PT test
This test represents the duration in which the extrinsic pathway takes place. A prolonged
PT time may signify an enhanced anticoagulant activity or chemical change to factor VII, X,
V, II, I (fibrinogen). Another value INR is also associated with PT test. INR value greater
than 1 shows delayed clotting. A typical range of INR for person not taking blood thinner
medication is 2 to 3.5.
PT test of the sample dressing were done at CWS hospital Rourkela. Anticoagulated
whole blood was collected and centrifuged at 4000g to isolate platelet poor plasma (PPP).
Now 2 ml of PPP was taken in eppendorf tubes containing dressing material and was
incubated at 37⁰C for 1 hour.
100ml of sample treated PPP was transferred to test cup and was further incubated at
37⁰C for 3 minutes and PT reagent was added 5 seconds prior to the end of incubation. PT
reagent was also incubated and kept at 37⁰C prior to use.
3.1.5 APTT test
APTT, also known as activated partial thromboplastin time is a medical test characterizing
blood coagulation. The APTT test was performed at CWS hospital, Rourkela.
Anticoagulated whole blood was collected and centrifuged at 4000g to isolate platelet poor
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plasma (PPP). Now 2 ml of PPP was taken in eppendorf tubes containing dressing material
and was incubated at 37⁰C for 1 hour. 100ml of sample treated PPP was transferred to test
cup and was further incubated at 37⁰C for 1 minute. 5 second prior to the incubation time
finishes, APTT reagent was added and incubated for 3moreminutes. Again calcium chloride
was added 5 seconds prior to the end of incubation.
3.1.6 Platelet Isolation and Adhesion
Whole blood was anticoagulated with trisodium citrate before collection. The anticoagulated
whole blood was incubated at 37⁰C for 15 minutes. Then the blood was collected in 15
ml polypropylene tubes and centrifuged at 800g for 15 minutes to separate blood cells and
platelet rich plasma (PRP). About 2 ml of PRP was collected from 15 ml whole blood. The
PRP is then mixed with PBS buffer at 1:3 ratio to increase the working volume. Now 100ml
of the working solution was poured on the dressing. The dressing is now incubated for 15
minutes. After incubation, dressings were dip rinsed in PBS buffer thrice. This removes
the unattached platelets from the dressings. To rupture the attached platelets, dressings were
put inside PBS buffer containing 1% TritonX100 surfactant. The surfactant is used for LDH
test to determine the percentage of platelets adhered to the dressings. A series of PRP with
different dilution was treated with TritonX100 to obtain a platelet dilution curve and was
compared to the sample data obtained to measure qualitatively the percentage of platelets
adhered.
3.1.7 Swelling Studies
The swelling capacity of the dressings was determined in trisodium citrated whole blood
and phosphate-buffered saline (PBS). The pre-weighed dry dressings (wini) were placed into
tissue culture wells containing either trisodium citrated whole blood or PBS. The dressings
were weighed at an interval of 2 min for 30 min (Wwet). The swelling ratio of the dressings
at each time interval was determined by the following formula:
Swellingratio =
Wwet  Winitial
Winitial
×100 (3.2)
3.2 Results and Discussion
Spontaneous complexation occurs when polymers containing opposite charges are allowed
to interact. This complexation happens at the interface of the polymer solutions and is a
result of strong electrostatic interaction existing between them. Polyelectrolyte complexes
(PECs) so formed do not solubilise in water and precipitate out. Sonication of the solution
then produces a homogenous PEC solution
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Figure 3.1: E-SEM image of (a) CA64, (b) CA73, (c) AC64 and (d) AC73 
 
Above images are the E-SEM images of sample CA64 and CA73, AC64 and AC73 
respectively, taken at a magnification of 700x. The images show highly porous structure. The 
surface appearance did not vary among CA64 and CA73. Similarly Surface structure of AC64 
and AC73 were found to be similar. 
 
3.2.1 Hemolysis Assay 
A hemolysis assay depicts the hemocompatibility of a material. Erythrocytes account for 
almost 40-45% of total blood volume. Any foreign material when exposed to blood from 
human body likely to cause change in local chemistry or/and concentration of blood. However 
a minute change in blood environment can cause erythrocytes to rupture and hemoglobin to get 
released to extracellular environment. Thus , it is essential for a dressing sample to be 
hemocompatible. 
Hemolysis percentage of a sample, if lies above 20% is considered hemolytic. From the 
aforementioned graph it is evident that pure alginate and chitosan sample show moderate 
hemolysis and a good hemocompatibility. PEC with higher chitosan concentration 
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Figure 3.2: Hemolysis Assay graph of PEC samples
have better hemocompatibility and hemocompatibility decreases with decrease in chitosan
concentration (increase in alginate concentration as well). It has been known that presence
of hydrophilic group renders the material to be less hemolytic [29], which can explain the
lesser hemolytic nature of pure chitosan and alginate samples. Sameway presence of cationic
surface charge promotes the adherence of RBCs among themselves and also decreases the
chance of hemolysis [30]. This explains the hemocompatibility of PEC with higher chitosan
concentration.
3.2.2 Blood Clotting Assay
The following graph shows the clotting rate of PEC samples.
OD values weremeasured at an interval of 3, 8, 13 and 18minutes. The slope of the graph
in various interval shows change in OD in between those time intervals and depicts the rate
of clotting. In whole blood , as seen from the graph, clotting rate starts to increase after 8
minutes, which is almost similar to sample C100. among PECs with increase in alginate
concentration onset of clotting happens earlier. In pure chitosan and sample CA73, steep
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Figure 3.3: Blood clotting Assay graph of PEC samples
slope in interval 13-18 shows , delayed onset of clotting but after onset , clotting becomes
faster. Among all , pure alginate sample showed fastest clotting even better than chitosan,
even though chitosan is famous for its thrombogenic effect.
3.2.3 PT test
The following graph shows the Prothrombin time, or the time taken for the extrinsic pathway
to complete. An abnormal PT time (usually above 24) is usually caused due to anomaly in
extrinsic pathway mechanism.
From the graph it is shown that for normal plasma the pt time shows 10 seconds. Scaffold
treated plasma delays the pt time maximum 8 seconds. Even though variance is not much,
the higher positive charge samples show more delay than lower positive charge samples.
Pure alginate showed the least delay.
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Figure 3.4: PT time test graph of PEC samples
3.2.4 APTT Test
The aforementioned graph shows delayed aptt time with higher chitosan concentration
samples. For normal platelet poor plasma, the aptt times vary around 43 seconds. And with
higher alginate concentration, aptt time tends to be lower. Even though chitosan is known to
be highly thrombogenic, the delayed time may be explained with The Vroman effect [31].
Vroman’s effect states that proteins with highest mobility in blood plasma , tend to
arrive first and afterwards are replaced by less motile proteins with higher affinity to the
surface. As per accepted notion and scientific studies the contact system is activated on
negatively charged surfaces and that negative charge density in blood plasma controls the
extent of the intensity of the contact activation in plasma confirming their positive corelation.
In high chitosan samples the net surface charge is positive and it attracts blood cells to
adhere to its surface frequently. Blood proteins are mostly negative and they tend to bind to
sample surface as well. However fibrinogen amount in blood is comparatively lower than
other blood protein like albumin. Thus at first the surface is flooded with abundant blood
proteins. But fibrinogen has higher affinity towards platelet plug- negative charged surface
and according to Vroman’s effect they replace the higher motile proteins afterwards and
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Figure 3.5: APTT time graph of PEC samples
initiate contact activation. This effect may be the explanation to the delayed aptt time in
higher chitosan samples.
3.2.5 Platelet Adhesion
High cationic surface charge on chitosan surface increases its ability to promote platelet
adhesion and activation which imparts to its procoagulant activity [32]. Activated platelets
provide a dense negative charge phospholipid surface for fibrinogen adherence activating
the platelets and thereafter the assembly of coagulation factor complexes and therefore
accelerate blood coagulation.
Some studies indicated that besides adherent platelets, platelets in the bulk blood can
also be activated when blood comes into contact with foreign materials.
Results indicate that pure chitosan showed the most platelet adherence and in PEC
samples with greater net positive charge on surface, greater adherence followed. It may be
due to the cationic surface effect of the the dressing samples. As shown, even higher alginate
samples also showed considerable platelet adherence. This may be due to the tendency of
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human blood cells to adhere to foreign materials in order to protect human body.
Platelets are cells without nucleus. When subjected to foreign surface or damaged
endothelium, however they form clumps and produce pseudopodium and adhere to the
surface [33]. The following FESEM image shows the adherence of platelets on a sample
surface as clumps.
Figure 3.6: Percentage of platelets adhered in PEC samples
3.2.6 Swelling Studies
The following graph shows the swelling ratio of PECs with time.
The graph shows the swelling behaviour of sample C100, CA73, CA64, CA55. sample
C100 got degraded on 3rd day however other PEC samples degraded on 4th day. C100
showed bes swelling ratio, highest being more than 50 times of its original weight. PEC
samples showed little lower swelling ratio, which varied in and around 35-40 times of
original weight. Sample CA64 started to lose water weight after first day itself. Below
graph shows swelling studies of sample A100, AC64 and AC73. While performing the
experiment, it was found that the sample A100 got dissolved in water instantly (within 10
minutes of start of the experiment.) However sample AC73 and sample AC64 retained their
23
Chapter 3 PEC samples
Figure 3.7: Swelling behaviour of C100, CA73, CA55 and CA64 (clock wise)
PEC structure for 2 days before degrading completely.
Figure 3.8: swelling behaviour of AC64, AC73 and A100 (clock wise)
Lower stability of high alginate PECs in PBS solution also questions , scaffold materials
strength into question in case of deep wound.
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3.3 Summary
From all the tests done on PEC samples, the results of hemolysis, platelet adhesion test and
swelling studies were better for PECs with high chitosan concentration. In all clotting related
tests like Prothrombin time, activated partial thromboplastin time it was found that positive
charge of chitosan delayed the sample induced test results in PECs with high chitosan
concentration. However the PEC samples with higher alginate proportions were found to
have very little to no effect on test results. In blood clotting assay, pure chitosan and high
chitosan concentration PECs showed delayed onset of clotting, though rate of clotting after
onset was fast. From all these results Samples with higher chitosan concentration were
chosen to be incorporated with clay mineral bentonite and further studies were carried out
to evaluate the efficacy of the PEC clay nanocomposite samples.
Chapter 4
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4.1 Materials and Methods
Cell culture tasted Chitosan with degree of deacetylation greater than 90% and molecular
biology grade sodium alginate were obtained from HiMedia. The test results were
compared with HemCon ChitoGauze® PRO and Quikclot advanced clotting sponge. PT
(Thromborel® S) and APTT (Actin FSL) reagents were obtained from Siemens Healthcare.
Human thrombin-antithrombin complex (TAT) ELISA kit was obtained from Qayee-Bio.
4.1.1 Preparation of PEC Dressing
Chitosan solution (1% W/V) was prepared in water. Hydrochloric acid (HCl) was added
dropwise to maintain acidic pH. Sodium alginate was dissolved in water. pH of chitosan
solution was maintained around 5. Clay bentonite powder was added to chitosan solution
and was stirred for 2 hours at high rotation for uniform mixing. Sodium alginate solution
prepared has an acidic pH as well (pH 6-6.5). Chitosan-clay solution was taken in a syringe
and dropwise added to alginate solution. Beads are formed in alginate base. Ultrasonification
of these samples were done to prepare an uniform mixture which is the resultant PEC
solution. The samples prepared were name S211, S311, S411 according to the chitosan ,
bentonite and alginate concentration respectively. These solutions were frozen at -200 C for
12 hours. Then the samples were lyophilised at -1200 C in a lyophilizer. Resultant scaffold
produced is the desired material to be tested. Scaffolds of pure chitosan and alginate were
also produced along wth simple PEC solutions. For characterisation study Environmental
Scanning Electron Microscope (E-SEM), study was carried out.
4.1.2 Hemolysis Assay
Hemolysis assay was taken from Mallick et al. [1]. 0.9% NaCl solution was prepared by
diluting common salt in water. This is known as physiological saline. Blood is diluted with
physiological saline in the ratio of 4:5. The resulting solution forms the stock solution.
The dressings were cut into equal sizes (12 mg each). The dressings were placed into
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polypropylene tubes and 0.5 mL of diluted blood was dispensed on them. Two different
control (positive and negative) were also made. Same amount of blood was added to both
control, while .01MHClwas added to the positive control rupturing the RBC fraction. All the
tubes were diluted with physiological saline by similar amount. The tubes were centrifuged
at 2000g for 20 minutes. OD of the supernatants was taken at 540 nm.
Hemolysis% = ODtest  OD ve
OD+ve  OD ve×100 (4.1)
Samples having hemolysis percentage <5% are highly hemocompatible, 5-20%
are slightly hemolytic and samples having hemolysis percentage above 20% are
non-hemocompatible.
4.1.3 Blood Clotting Assay
The whole blood clotting assay was taken from Shih et al. [2]. The dressings were placed
into 50 mL polypropylene tubes and pre-warmed to 37⁰C. 200 μL of anticoagulated whole
blood was then dispensed onto the dressings. 20 μL of 0.2 M calcium chloride was added
to initiate coagulation. After 10 min incubation at 37ºC and 30 rpm, the RBCs that were not
trapped in the clot were hemolysed by pouring 25 mL distilled water slowly along the walls
of the tube. This was done in an interval of 5, 10, 15, 20 minutes. The absorbance (OD) of
the resulting hemoglobin solution was taken at 540 nm.
4.1.4 PT test
This test represents the duration in which the extrinsic pathway takes place. A prolonged
PT time may signify an enhanced anticoagulant activity or chemical change to factor VII, X,
V, II, I (fibrinogen). Another value INR is also associated with PT test. INR value greater
than 1 shows delayed clotting. A typical range of INR for person not taking blood thinner
medication is 2 to 3.5.
PT test of the sample dressing were done at CWS hospital Rourkela. Anticoagulated
whole blood was collected and centrifuged at 4000g to isolate platelet poor plasma (PPP).
Now 2 ml of PPP was taken in eppendorf tubes containing dressing material and was
incubated at 37⁰C for 1 hour.
100ml of sample treated PPP was transferred to test cup and was further incubated at
37⁰C for 3 minutes and PT reagent was added 5 seconds prior to the end of incubation. PT
reagent was also incubated and kept at 37⁰C prior to use.
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4.1.5 APTT test
APTT, also known as activated partial thromboplastin time is a medical test characterizing
blood coagulation. The APTT test was performed at CWS hospital, Rourkela.
Anticoagulated whole blood was collected and centrifuged at 4000g to isolate platelet poor
plasma (PPP). Now 2 ml of PPP was taken in eppendorf tubes containing dressing material
and was incubated at 37⁰C for 1 hour. 100ml of sample treated PPP was transferred to test
cup and was further incubated at 37⁰C for 1 minute. 5 second prior to the incubation time
finishes, APTT reagent was added and incubated for 3moreminutes. Again calcium chloride
was added 5 seconds prior to the end of incubation.
4.1.6 Platelet Isolation and Adhesion
Whole blood was anticoagulated with trisodium citrate before collection. The anticoagulated
whole blood was incubated at 37⁰C for 15 minutes. Then the blood was collected in 15
ml polypropylene tubes and centrifuged at 800g for 15 minutes to separate blood cells and
platelet rich plasma (PRP). About 2 ml of PRP was collected from 15 ml whole blood. The
PRP is then mixed with PBS buffer at 1:3 ratio to increase the working volume. Now 100ml
of the working solution was poured on the dressing. The dressing is now incubated for 15
minutes. After incubation, dressings were dip rinsed in PBS buffer thrice. This removes
the unattached platelets from the dressings. To rupture the attached platelets, dressings were
put inside PBS buffer containing 1% TritonX100 surfactant. The surfactant is used for LDH
test to determine the percentage of platelets adhered to the dressings. A series of PRP with
different dilution was treated with TritonX100 to obtain a platelet dilution curve and was
compared to the sample data obtained to measure qualitatively the percentage of platelets
adhered.
4.1.7 Thrombin Generation
Heparin, 15 U/mL, was used to collect whole blood. Heparinised whole blood was
centrifuged at 1500g for 20 min. The plasma supernatant was separated from the RBC
fraction. 1 mL of this plasma was poured over the dressings and incubated for 30 min at 37ºC
for thrombin generation. The amount of antithrombin generated to neutralise the available
thrombin in the dressings was determined using the amount of thrombin-antithrombin (TAT)
complex produced with the help of ELISA kit according to manufacturer’s instructions.
4.1.8 Swelling Studies
The swelling capacity of the dressings was determined in trisodium citrated whole blood
and phosphate-buffered saline (PBS). The pre-weighed dry dressings (wini) were placed into
tissue culture wells containing either trisodium citrated whole blood or PBS. The dressings
28
Chapter 4 PEC-clay nanocomposite sample
were weighed at an interval of 2 min for 30 min (Wwet). The swelling ratio of the dressings
at each time interval was determined by the following formula:
Swellingratio =
Wwet  Winitial
Winitial
×100 (4.2)
4.2 Results and Discussion
4.2.1 E-SEM
(a) (b)
Figure 4.1: E-SEM image of sample S211, S311
Figure 4.2: E-SEM image of sample S411
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Figure 4.3: Hemolysis assay of nanocomposite samples
4.2.2 Hemolysis Assay
From the hemolysis study of bentonite incorporated samples, it is clear that inclusion
of hemolysis on material doesn’t have any hemolytic effect on blood erythrocytes, and
percentage hemolysis was found to be less than 5% in case of all nanocomposite samples.
Among the nanocomposites itself, the samples with higher cationic charge tend to show
higher hemocompatibility. Comparing with the results obtained from Quickclot and
Chitogauge, the samples are found to have competitive hemocompatibility characteristics.
4.2.3 Blood clotting assay
The following graph shows the clotting rate of nanocomposite samples. From the graph it
is clear that sample S211 shows the best clotting rate. Incorporation of bentonite induces
higher clotting rate.
Sample S411 shows the least clotting rate , even so it has comparable clotting rate to
Quikclot. The slower clotting rate can be described by delay in activation of clotting cascade
due to higher positive charge of the sample thereby causing Vroman’s effect.
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Figure 4.4: Blood clotting assay of nanocomposite samples
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4.2.4 PT test
The following graph shows the time taken for the intrinsic pathway to get completed in
nanocomposite samples which in turn depicts the sample induced variations in extrinsic
pathway of blood clotting, if any.
Figure 4.5: PT test of nanocomposite Samples
The graph compares nanocomposite samples with PEC samples and control samples i.e.
Quikclot and Chitogauge. Bentonite incorporated samples showed the best result. The delay
in PT time was least in sample S211, which was almost similar to normal blood plasma. In
sample S411 , a little delay in PT time occurred but was lower than PEC samples and control
samples as well. This shows that , Bentonite clay incorporation in PEC tends to improve PT
time in dressing samples.
4.2.5 APTT Test
Similar to the PEC samples, from the aforementioned graph it is evident that surface positive
charge has adverse effect on aptt time. The nanocomposite sample S211 , having the highest
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Figure 4.6: APTT test of nanocomposite samples
surface positive charge imparts a delay in aptt time. Sample S211 has almost no effect in
normal intrinsic mechanism.
Among control samples, Quikclot showed a delayed aptt time. Chitogauge however
has normal aptt time. The delayed time is explained by Vroman’s effect, which shows no
appreciable change or manipulation in the mechanism of intrinsic pathway but a little delay
in contact activation which thereby delays the completion of the pathway. This shows that ,
Bentonite clay incorporation in PEC tends to improve PT time in dressing samples.
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Figure 4.7: Percentage Platelet Adhesion on nanocomposite samples
4.2.6 Platelet Adhesion
As seen from the graph , nanocomposite sample S411 showed the better platelet adhesion
and percentage platelet adhesion decreased with decrease chitosan concentration. In any
case percentage of platelets adhered was above 30 percent and below 70%. As indicated in
previous studies, platelets in the bulk blood can also be activated when blood comes into
contact with foreign materials, which explains minimum 30% platelet adherence in all the
samples despite net effective negative charge.
The following FESEM images show the platelet adherence to nanocomposite sample
surface.
From the aforementioned FESEM images, platelets are seen to form clumps and are
adhered to each other and sample surface as well, with pseudopodia.
34
Chapter 4   PEC-clay nanocomposite sample 
35 
 
                                                                                                                                 
 (a) (b) 
Figure 4.8: Platelet adherence on sample S211, S311 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Platelet adherence on sample S411 
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4.2.7 Thrombin Generation
Figure 4.10: Thrombin generation graph of nanocomposite dressings
From the test samples, it is shown that all the samples promoted thrombin generation.
Test sample chitogauge had the highest thrombin generation followed by sample S211, then
AC73. Thrombin generation data is almost positively corelated with negative charge of
sample. Among nanocomposite samples thrombin generation varied as S211 >S311 = S411.
4.2.8 Swelling studies
The following graph shows the swelling behaviour of the PEC-clay nanocomposite samples.
From the graph it is evident that all the Nanocomposite samples swelling ratio was lower
than PEc samples. However their degradation didn’t happen even until 5 days. Sample
S211 maintained their saturated swelling state almost the entire time of the study. To verify
the structural integrity of nanocomposite samples, sample dressings were dipped in blood
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Figure 4.11: Swelling behaviour of S211, S311, S411 (clock wise)
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Figure 4.12: Image showing shape change in PEC clay sample compared to PEC sample
plasma for 6 hours and change in shape was observed. The same was compared with that
of PEC structures. It was found that nanocomposite samples shape didn’t change much ,
however PEC samples swelled heavily and change in shape was clearly visible.
Also from the swelling study it is known that PEC-clay nanocomposite samples initially
absorbed water and attended peak value within 30 minutes. Even after 4 days they did not
lose their integrity and carried almost same weight which was not the case of PEC samples.
In alginate , sample dissolved and in chitosan too much swelling was observed. However
chitosan changed its structure as it absorbed more plasma in the test. The structural integrity
in nanocomposite samples may be explained by stable layered structure of clay mineral
incorporated in PEC samples.
4.3 Summary
All the tests performed show that net positive charge on sample surface affected some test
results. Sample S211 was better in case of PT and APTT results. However Sample S411
was better in case of platelet adhesion and hemolysis studies. Sample S211 also showed best
clotting rate which was better than control materials as well.
Chapter 5
Conclusion
Induction of clay mineral into PEC dressing sample generates positive results in all tests.
Results signify that net positive charge on dressing sample has adverse effect on clotting
rate, due to Absorption dilution effect. However the higher the positive charge, the higher
hemocompatibility and platelet adhesion.
However it is evident from these tests that bentonite is an excellent thrombogenic
material. Its incorporation into PEC dressing yielded better results than simple PEC
dressings. Future studies on the material with varied concentration can result in a product
with optimum results in all tests which can be best effective as wound dressing material.
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